Published in N Engl J Med on September 20, 2012
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis (DEFINE) | NCT00420212
Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers | NCT02683863
Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis (PRAG-MS) | NCT03345940
The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev (2013) 3.40
The Diagnosis and Treatment of Optic Neuritis. Dtsch Arztebl Int (2015) 2.21
Thiamine deficiency promotes T cell infiltration in experimental autoimmune encephalomyelitis: the involvement of CCL2. J Immunol (2014) 2.07
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol (2015) 1.88
The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front Oncol (2012) 1.64
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry (2014) 1.61
Multiple sclerosis-a quiet revolution. Nat Rev Neurol (2015) 1.47
Dimethyl Fumarate Ameliorates Lewis Rat Experimental Autoimmune Neuritis and Mediates Axonal Protection. PLoS One (2015) 1.46
Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm (2015) 1.44
Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol (2013) 1.43
Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial. PLoS One (2016) 1.41
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol (2015) 1.28
Dimethyl fumarate associated lymphopenia in clinical practice. Mult Scler (2014) 1.24
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J Clin Invest (2014) 1.24
Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration. Biol Open (2013) 1.20
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol (2013) 1.18
Redox regulation of antioxidants, autophagy, and the response to stress: implications for electrophile therapeutics. Free Radic Biol Med (2014) 1.18
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol (2014) 1.18
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol (2013) 1.17
Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol (2013) 1.16
Cell type-specific Nrf2 expression in multiple sclerosis lesions. Acta Neuropathol (2015) 1.15
Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol (2016) 1.12
The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol (2014) 1.11
Remyelination therapy for multiple sclerosis. Neurotherapeutics (2013) 1.08
Oral BG-12 in multiple sclerosis. N Engl J Med (2013) 1.06
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther (2014) 1.05
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Mult Scler (2015) 1.05
NRF2 promotes neuronal survival in neurodegeneration and acute nerve damage. J Clin Invest (2015) 1.05
Defining and scoring response to IFN-β in multiple sclerosis. Nat Rev Neurol (2013) 1.04
Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci U S A (2016) 1.02
Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis. PLoS One (2015) 1.00
NRF2-regulation in brain health and disease: implication of cerebral inflammation. Neuropharmacology (2013) 1.00
Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol (2014) 1.00
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. Mult Scler J Exp Transl Clin (2015) 1.00
Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. Ann Neurol (2015) 0.99
Propofol activation of the Nrf2 pathway is associated with amelioration of acute lung injury in a rat liver transplantation model. Oxid Med Cell Longev (2014) 0.99
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol (2014) 0.97
Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord (2015) 0.97
Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits. Drug Healthc Patient Saf (2013) 0.97
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol (2014) 0.97
Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview. Ther Adv Neurol Disord (2015) 0.95
Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies. Clin Exp Immunol (2014) 0.95
An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations. Patient Prefer Adherence (2015) 0.94
Preferred features of oral treatments and predictors of non-adherence: two web-based choice experiments in multiple sclerosis patients. Interact J Med Res (2015) 0.94
Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun (2016) 0.94
Immune surveillance of the central nervous system in multiple sclerosis--relevance for therapy and experimental models. J Neuroimmunol (2014) 0.93
Nrf2 upregulates ATP binding cassette transporter expression and activity at the blood-brain and blood-spinal cord barriers. J Neurosci (2014) 0.92
Current and future therapies for multiple sclerosis. Scientifica (Cairo) (2013) 0.92
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biologics (2013) 0.92
Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple Sclerosis. Oxid Med Cell Longev (2015) 0.92
Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm (2015) 0.91
Promoting remyelination in multiple sclerosis-recent advances. Drugs (2013) 0.91
Body-worn sensors capture variability, but not decline, of gait and balance measures in multiple sclerosis over 18 months. Gait Posture (2013) 0.90
Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate. Drug Des Devel Ther (2014) 0.90
Dimethyl fumarate protects pancreatic islet cells and non-endocrine tissue in L-arginine-induced chronic pancreatitis. PLoS One (2014) 0.90
No quiet surrender: molecular guardians in multiple sclerosis brain. J Clin Invest (2015) 0.90
Multiple sclerosis treatment and infectious issues: update 2013. Clin Exp Immunol (2014) 0.90
Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 system during cellular stress. J Biol Chem (2017) 0.90
The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis. Ther Adv Neurol Disord (2014) 0.89
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis. Eur J Neurol (2015) 0.89
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology (2015) 0.88
Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis. J Neurol (2014) 0.88
Regulation of dimethyl-fumarate toxicity by proteasome inhibitors. Cancer Biol Ther (2014) 0.88
Preferential Recruitment of Neutrophils into the Cerebellum and Brainstem Contributes to the Atypical Experimental Autoimmune Encephalomyelitis Phenotype. J Immunol (2015) 0.88
Risk evaluation and monitoring in multiple sclerosis therapeutics. Mult Scler (2013) 0.88
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World J Clin Cases (2015) 0.88
Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate. BMC Neurol (2015) 0.87
GPR109A and vascular inflammation. Curr Atheroscler Rep (2013) 0.87
Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis. J Cent Nerv Syst Dis (2014) 0.87
Metabolic reprograming of mononuclear phagocytes in progressive multiple sclerosis. Front Immunol (2015) 0.87
Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol (2016) 0.86
Monomethylfumarate induces γ-globin expression and fetal hemoglobin production in cultured human retinal pigment epithelial (RPE) and erythroid cells, and in intact retina. Invest Ophthalmol Vis Sci (2014) 0.86
Anti-inflammatory dimethylfumarate: a potential new therapy for asthma? Mediators Inflamm (2013) 0.86
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. Int J MS Care (2015) 0.86
Bridging, switching or drug holidays - how to treat a patient who stops natalizumab? Ther Clin Risk Manag (2013) 0.85
Dimethylfumarate suppresses adipogenic differentiation in 3T3-L1 preadipocytes through inhibition of STAT3 activity. PLoS One (2013) 0.85
Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy. Ther Adv Chronic Dis (2016) 0.85
Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis. Drug Des Devel Ther (2014) 0.85
Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag (2014) 0.85
Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study. Ther Adv Neurol Disord (2014) 0.84
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol (2012) 0.84
Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment. Patient Prefer Adherence (2014) 0.84
The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology (2016) 0.84
Multiple sclerosis: oral BG12 for treatment of relapsing-remitting MS. Nat Rev Neurol (2012) 0.84
Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations. Neurol Clin Pract (2016) 0.84
Keap1/Nrf2 pathway activation leads to a repressed hepatic gluconeogenic and lipogenic program in mice on a high-fat diet. Arch Biochem Biophys (2015) 0.84
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Mult Scler (2014) 0.83
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. Neurol Ther (2015) 0.83
Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy. Crit Rev Immunol (2013) 0.83
12/15-Lipoxygenase-mediated enzymatic lipid oxidation regulates DC maturation and function. J Clin Invest (2015) 0.83
Multiple sclerosis: overview of disease-modifying agents. Perspect Medicin Chem (2014) 0.82
Monomethylfumarate reduces in vitro migration of mononuclear cells. Neurol Sci (2014) 0.82
Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS? PLoS One (2015) 0.82
Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations. Ther Clin Risk Manag (2016) 0.82
Fumaric acid esters stimulate astrocytic VEGF expression through HIF-1α and Nrf2. PLoS One (2013) 0.82
Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis. Neurol Neuroimmunol Neuroinflamm (2017) 0.82
Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS. Nat Rev Neurol (2013) 0.82
Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis. Drugs (2015) 0.82
Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade. J Clin Med (2015) 0.82
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med (2010) 13.70
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet (2009) 7.16
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med (2012) 6.51
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol (2010) 5.03
Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med (2011) 4.93
A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res (2010) 4.77
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet (2009) 3.92
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet (2008) 3.68
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med (2012) 3.16
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet (2013) 2.89
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol (2009) 2.82
Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol (2007) 2.68
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol (2012) 2.68
Manufacturer's response to case reports of PML. N Engl J Med (2013) 2.65
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med (2007) 2.64
Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain (2003) 2.63
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol (2006) 2.62
Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol (2005) 2.55
Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol (2014) 2.51
Evidence for acute neurotoxicity after chemotherapy. Ann Neurol (2010) 2.45
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler (2010) 2.45
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology (2014) 2.41
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med (2012) 2.36
The clinical significance of an intrathecal monoclonal immunoglobulin band: a follow-up study. Neurology (2003) 2.35
MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol (2011) 2.12
Testicular hypofunction and multiple sclerosis risk: a record-linkage study. Ann Neurol (2014) 2.09
Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol (2010) 2.08
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler (2011) 2.07
Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol (2006) 2.06
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol (2011) 1.92
Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol (2004) 1.89
Immune regulation of multiple sclerosis by transdermally applied myelin peptides. Ann Neurol (2010) 1.89
Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Hum Genet (2010) 1.89
Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol (2007) 1.88
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol (2007) 1.86
Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol (2008) 1.85
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol (2013) 1.83
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol (2011) 1.79
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis. J Neuroimmunol (2005) 1.76
The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol (2004) 1.76
Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy. J Neurol (2008) 1.75
Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med (2014) 1.75
Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci (2013) 1.74
Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol (2007) 1.73
Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol (2009) 1.73
Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia (2012) 1.73
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain (2010) 1.71
The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Mult Scler (2012) 1.71
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med (2007) 1.69
Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol (2010) 1.64
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 1.62
Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol (2012) 1.61
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest (2003) 1.59
NeuriteTracer: a novel ImageJ plugin for automated quantification of neurite outgrowth. J Neurosci Methods (2007) 1.59
Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol (2008) 1.58
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler (2011) 1.57
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler (2012) 1.55
Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. J Am Coll Cardiol (2010) 1.55
Proton magnetic resonance spectroscopic imaging can predict length of survival in patients with supratentorial gliomas. Neurosurgery (2003) 1.54
Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis. Arch Neurol (2010) 1.51
Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. Clin Neurophysiol (2011) 1.51
Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging. Med Image Anal (2012) 1.50
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol (2009) 1.50
The therapeutic potential of cannabis. Lancet Neurol (2003) 1.49
TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. J Immunol (2011) 1.47
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol (2013) 1.47
Seeing injectable MS therapies differently: they are more similar than different. Neurology (2009) 1.47
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler (2012) 1.46